BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy

Marcel Wiesweg, Cedric Preuß, Julia Roeper, Martin Metzenmacher, Wilfried Eberhardt, Ursula Stropiep, K. Wedeken, Henning Reis, Thomas Herold, Kaid Darwiche, Clemens Aigner, Martin Stuschke, Hans‐Ulrich Schildhaus, Kurt Werner Schmid, Markus Falk, Lukas C. Heukamp, Markus Tiemann, Frank Griesinger, Martin Schüler